Compare Johnson & Johnson (JNJ) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs ProShares UltraPro QQQ ETF — how do they compare? Johnson & Johnson trades at $250.31 (market cap $598.96B), while ProShares UltraPro QQQ ETF trades at $70.81. The key difference: Johnson & Johnson pays a 2.15% dividend while ProShares UltraPro QQQ ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, ProShares UltraPro QQQ ETF nearer its low. Which is the better fit depends on your goals.
| JNJ | TQQQ | |
|---|---|---|
Market Cap | $598.96B | — |
Volume | 6,156,228 | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $267.24 | $87.22 |
52-Week Low | $164.36 | $37.89 |
Enterprise Value | $631.90B | — |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
TQQQ trades at $67.65, up 0.18% on the day, with a bearish technical signal driven by moving averages. The ETF faces structural costs and volatility risks, as highlighted in recent news. Key support lies at $66, with resistance at $69. Recent articles emphasize the amplified downside potential during market selloffs, questioning the long-term viability of leveraged strategies.
Outlook remains cautious due to high volatility and compounding costs. Opportunities exist for tactical traders during uptrends, but risks include severe drawdowns and daily rebalancing effects. Investors should weigh the 3x leverage against potential wealth destruction in downturns, as seen in 2022's 81% drop versus Nasdaq's 33% decline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
